Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 27, 2004 Phil Wohl	Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.
The Motley Fool January 7, 2010 Gerard Torres	Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.
The Motley Fool March 23, 2011 Andrew Bond	What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.
The Motley Fool October 2, 2007 Lawrence A. Rothman	Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.
The Motley Fool September 30, 2009 Chris Jones	A Tough Pill to Swallow Health-care reform's shadow of uncertainty looms over Walgreen's productive fiscal year.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool March 26, 2007 Ryan Fuhrmann	Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool March 24, 2011 Rick Aristotle Munarriz	It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool October 8, 2011 Shubh Datta	Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide.
The Motley Fool October 7, 2010	DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio.
The Motley Fool January 13, 2004 Alyce Lomax	CVS Fever Drug stores benefit from the flu bug, but for how much longer?
The Motley Fool September 21, 2006 Nathan Parmelee	Wal-Mart Goes Generic The supposed most terrible retailer of all is doing a very good thing with generic drug sales. The program will, of course, benefit Wal-Mart by creating additional traffic to its stores. This move could change the game for a number of retailers over the next few years.
The Motley Fool June 10, 2010 Claire Stephanic	CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers.
The Motley Fool June 26, 2007 Ryan Fuhrmann	Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool July 29, 2011 Shubh Datta	A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy.
The Motley Fool January 3, 2012 Shubh Datta	Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts.
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool October 5, 2007 Timothy M. Otte	CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.
The Motley Fool January 13, 2009 Dayana Yochim	Fiscal Fitness '09: 6 Ways to Score Cheap(er) Drugs Save more than $200 on prescriptions.
The Motley Fool August 15, 2007 Mary Dalrymple	Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money.
The Motley Fool July 6, 2007 Lawrence Rothman	Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.
The Motley Fool October 6, 2004 Steven Mallas	Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool November 8, 2006 Michael P. Cecil	CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.
The Motley Fool September 28, 2007 Timothy M. Otte	Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
The Motley Fool June 29, 2006 Ryan Fuhrmann	Walgreen's Prescription for Growth The drugstore chain continues to roll, even if it is a bit pricey. Great companies rarely trade at bargain-basement levels. But if savvy investors keep a watchful eye, they may find an opportunity to pick up some shares at a fairer price.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool September 27, 2005 Nathan Slaughter	All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors.
The Motley Fool October 6, 2010 Rich Smith	This Just In: Upgrades and Downgrades Jefferies on Walgreen: Take two shares and thank me in the morning.
The Motley Fool July 14, 2008 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: CVS Caremark... Paychex... Walgreen... Cummins...
The Motley Fool June 10, 2004 Alyce Lomax	Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.
The Motley Fool January 4, 2008 Timothy M. Otte	Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool March 26, 2010 Cathy Applefeld Olson	Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup.
The Motley Fool June 24, 2011 Shubh Datta	A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term.
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool April 4, 2007 Timothy M. Otte	Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.
The Motley Fool October 31, 2008 Timothy M. Otte	CVS Caremark Takes Care of Its Investors The drugstore giant continues to scoop up market share.
The Motley Fool October 4, 2005 Seth Jayson	Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.